US Stock Market Move | AI will be used to develop weight loss drugs, and Novo Nordisk A/S Sponsored ADR Class B (NVO.US) has increased by nearly 2% against the trend.

On Friday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose nearly 2% against the market trend, closing at $86.77 USD. In terms of news, the company and the U.S. technology company Valo Health recently announced their agreement to expand the scope of their collaboration to develop up to 11 drugs by 2023, utilizing human data and artificial intelligence (AI) to develop up to 20 new therapies for obesity, type 2 diabetes, and cardiovascular diseases.